Caiqi Liu^*, Ci Han^†, Jinfeng Liu^‡

Oncology Research, Vol.27, No.8, pp. 965-978, 2019, DOI:10.3727/096504019X15498329881440

Abstract Toll-like receptors (TLRs) are associated with tumor growth and immunosuppression, as well as apoptosis and immune system activation. TLRs can activate apoptosis and innate and adaptive immunity pathways, which can be pharmacologically targeted for the development of anticancer oncotherapies. Several studies and clinical trials indicate that TLR agonists are promising adjuvants or elements of novel therapies, particularly when used in conjunction with chemotherapy or radiotherapy. An increasing number of studies suggest that the activation of TLRs in various cancer types is related to oncotherapy; however, before this finding can be applied to clinical practice, additional More >

Pei Yin^*1, Jinpeng Jia^†1, Jijun Li^*, Yan Song^*, Yiyan Zhang^*, Fengkun Chen^*

Oncology Research, Vol.24, No.1, pp. 65-72, 2016, DOI:10.3727/096504016X14587366983838

Abstract Renal cell carcinoma (RCC) is the most common malignancy in the kidney in the world, and the 5-year overall survival for patients remains poor due to the lack of effective treatment strategies. Although ABT-737, as a Bcl-2/Bcl-xL inhibitor, has recently emerged as a novel cancer therapeutic reagent, apoptosis induced by ABT-737 is often blocked in several types of cancer cells. This study investigated whether the combination of the small-molecule BH3 mimetic ABT-737 and the lysosome inhibitor chloroquine was an effective strategy for treating renal cancer cells. We found that the combination of ABT-737 and chloroquine… More >